Company intelligence / Profile preview
Lepu Biopharma Co., Ltd.
Shanghai, Shanghai, Chinalepubiopharma.com ↗
- Ownership
- Public · 02157.HK
- Employees
- ~498
- Development stage
- Other
01
Overview
The company has multiple clinical-stage candidates including MRG003 (EGFR-targeted ADC), MRG002 (HER2-targeted ADC), MRG004A (TF-targeted ADC), and immunotherapy products
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)monoclonal antibodies (mAbs)oncolytic virus drugsimmunotherapies
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
Taizhou Hanzhong and AkesoI-Mab ShanghaiHan X
04
Financials
- Market cap
- $662.9M
- Total revenue
- $136.5M
- Enterprise value
- $721.6M
Beyond the preview
Go deeper on Lepu Biopharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lepu Biopharma Co., Ltd..